Cybrids that express mitochondrial genes from patients with progressive supranuclear palsy and multisystem atrophy manifest deficient complex I catalytic activity and (at least in the case of progressive supranuclear palsy) increased oxidative stress.
Cybrids in Alzheimer's disease: a cellular model of the disease?
Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids.
Alzheimer's disease cybrids replicate [beta]-amyloid abnormalities through cell death pathways.
Reduced complex I activity in parkinsonian cybrids.
Oxidative stress reduces the mitochondrial membrane potentials in Parkinson's and Alzheimer's disease cybrids.
This review focuses on the potential role of mitochondrial DNA (mtDNA)-related mitochondrial dysfunction in the late-onset, sporadic neurodegenerative diseases and describes the cybrid technique, a research tool useful for studying mtDNA genotype-phenotype relationships.
THE CYBRID TECHNIQUE AND ITS CONTRIBUTION TO NEURODEGENERATION RESEARCH
Cybrids derived from patients with mitochondrial disease are powerful tools for drug discovery, particularly when used in conjunction with functional assays for rapid screening of compounds.
To date, a number of expressed genetic sequences and active compounds have been discovered at MitoKor through the study of cybrids derived from Alzheimer's patients.
The Company intends to continue to provide rho-zero cells and cybrids to scientists within the research community.